Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2

Nimanthi Jayathilaka1,2,*, Aidong Han1, Kevin J. Gaffney3, Raja Dey1, Jamie A. Jarusiewicz3, Kaori Noridomi1,3, Michael A. Philips1, Xiao Lei1,2, Ju He1, Jun Ye1, Tao Gao1, Nicos A. Petasis3,4,5 and Lin Chen1,2,3,4,6,*

1Molecular and Computational Biology, Department of Biological Sciences, 2Program in Genetic, Molecular & Cellular Biology, 3Department of Chemistry, 4Norris Comprehensive Cancer Center, Keck School of Medicine, 5Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, CA 90089, USA and 6Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiang Ya Hospital, Central South University, Changsha, Hunan 410008, China

Received August 13, 2011; Revised January 17, 2012; Accepted February 8, 2012

ABSTRACT
Enzymes that modify the epigenetic status of cells provide attractive targets for therapy in various diseases. The therapeutic development of epigenetic modulators, however, has been largely limited to direct targeting of catalytic active site conserved across multiple members of an enzyme family, which complicates mechanistic studies and drug development. Class IIa histone deacetylases (HDACs) are a group of epigenetic enzymes that depends on interaction with Myocyte Enhancer Factor-2 (MEF2) for their recruitment to specific genomic loci. Targeting this interaction presents an alternative approach to inhibiting this class of HDACs. We have used structural and functional approaches to identify and characterize a group of small molecules that indirectly target class IIa HDACs by blocking their interaction with MEF2 on DNA. We used X-ray crystallography and 19F NMR to show that these compounds directly bind to MEF2. We have also shown that the small molecules blocked the recruitment of class IIa HDACs to MEF2-targeted genes to enhance the expression of those targets. These compounds can be used as tools to study MEF2 and class IIa HDACs in vivo and as leads for drug development.

INTRODUCTION
Alterations of epigenetic regulation are a characteristic of many diseases. Small molecules that are being developed as drugs against these diseases often function by modulating the epigenetic control of cellular processes (1). This approach of drug design is best exemplified by the discovery and development of small molecule inhibitors of histone deacetylases (HDACs) that show anti-tumor activity as well as therapeutic effects in neurodegenerative diseases and inflammation (1). HDACs deacetylate histone and non-histone proteins and are a major class of epigenetic regulators of diverse cellular processes. This family of enzymes can be phylogenetically divided into four classes: class I (HDAC1, 2, 3 and 8), class II (HDAC4, 5, 7, 9, 6 and 10) and class IV (HDAC 11), while class III (sirtuins, Sirt1-Sirt7) represents a structurally and functionally distinct family of HDAC enzymes. Most of the currently available HDAC inhibitors target the zinc-containing catalytic domain common to class I, II and IV HDACs, while some of these inhibitors appear to have limited isoform selectivity (2). In general, the broad inhibition of HDACs using active site inhibitors leads to complex cellular responses, which complicate mechanistic analyses and may explain some of the undesired side effects of these drugs in clinical applications (1). Therefore, it is important to develop inhibitors that specifically target a particular member or subset of HDACs to dissect the in vivo functions of HDACs and to explore, and eventually exploit, the full therapeutic potential of HDAC inhibition in a wide range of diseases.

Class II HDACs can be further divided into class IIa (HDAC4, 5, 7 and 9) and IIb (HDAC6 and 10). Class IIa HDACs are highly expressed in muscle cells, neurons and T cells. Extensive genetic studies have demonstrated the important physiological roles of these HDACs in development and adaptive responses of the muscle, nervous and immune systems (3–8) where they participate in calcium-dependent transcriptional responses (9,10).
These findings have drawn attention to the functional mechanisms of class IIa HDACs in those systems and their potential as therapeutic targets (11). However, recent studies reveal that class IIa HDACs do not respond to most of the existing HDAC inhibitors (2). In fact, compared with class I HDACs, class IIa HDACs have a catalytic domain that is less active, leading to the hypothesis that class IIa HDACs may function as acetyllysine receptors (2). These observations emphasize the need to develop specific inhibitors of this class for mechanistic studies and therapeutic development. They also raise the question of whether it is more effective to develop subtype-specific inhibitors of class IIa HDACs by focusing on functions other than the catalytic deacetylase activity of the protein.

Class IIa HDACs contain a unique regulatory domain N-terminal to the catalytic domain, which is absent in other HDAC members. This regulatory domain mediates interactions with a variety of other proteins, one of which is the MADS-box family of transcription factor Myocyte Enhancer Factor-2 (MEF2A-D). MEF2 plays a central role in the development and adaptive response of diverse tissues and organs (12); it is also selectively targeted for mutations in several types of cancers (13–16). Class IIa HDACs do not bind to DNA but depend on their interaction with the sequence-specific transcription factor MEF2 for genomic targeting (17,18). This interaction is mediated by a short amphipathic helix conserved in the N-terminal regulatory domain of class IIa HDACs. Crystallography analyses and in vitro biochemical studies reveal that the amphipathic helix binds to a highly conserved hydrophobic groove on the MADS-box/MEF2 domain of MEF2 (19–21). These studies suggest that small molecules binding to the hydrophobic pocket of MEF2 could block the recruitment of class IIa HDACs to DNA, thereby inhibiting the function of class IIa HDACs.

In this study, we used a structure-guided and mechanism-based approach to identify and characterize small molecule compounds that inhibit the MEF2: class IIa HDAC interaction. Our results reveal that these compounds can directly bind the MADS-box domain of MEF2 and prevent the recruitment of class IIa HDACs to the target genes and alter the expression of MEF2 target genes. Therefore, our findings suggest that MEF2 is a potential target for small molecule-based modulation of epigenetic regulation of specific gene expression in specific tissues.

MATERIALS AND METHODS

Drug treatment and luciferase assay

For the two-hybrid assay, cells were treated with 10 μM drug overnight unless indicated otherwise. The amount of DMSO was kept below 0.2% V/V. A luciferase assay was performed according to the manufacturer’s protocol (Promega). The luciferase response was normalized against the Renilla Luciferase as an internal control. The data are presented as a mean ± SD (n = 2) of normalized HDAC4:MEF2 luciferase response against the normalized response values for GAL4-VP16 for each condition to correct for non-specific inhibition of the luciferase signal.

Compound synthesis and preparation

BML-210 was purchased from Enzo Life Sciences. NKL02, NKL08, NKL09, NKL11, NKL13, NKL22, NKL30, NKL54 and NAP1407 were synthesized as shown in Supplementary Figure S2. Stock solutions for BML-210 (Enzo Life Sciences) and analogs were made at 10 mM concentration by dissolving in 100% DMSO and stored at −20°C. TSA (Enzo Life Sciences) was dissolved in DMSO as a 100 μM stock solution and stored at −20°C.

19F NMR

The experimental protocol is similar to that published (22). The NMR samples were prepared in an aqueous (pH 7.66) buffer containing 10 mM HEPES, 250 mM NaCl and 1 mM EDTA. Sample volumes were 700 μL. NKL54 solution was made by serial dilution of 10 mM NKL54 in 100% DMSO. NKL54 at 0.5–5 μM was incubated with MEF2A (1–95) at 0.5–10 μM for 30 min, and the 19F NMR spectra were acquired on a Varian VNMRS 500 Spectrometer at 25°C using a 54° pulse with total acquisition and delay time of 1.6 s for 3000 scans (80 min acquisition time). An internal capillary containing DMSO-d6 was used to obtain a lock signal. A spectral width of 10 ppm was used, and the data were multiplied with an exponential function of 0.2 Hz prior to Fourier transformation. The CF3 resonance of the free NKL54 was at −62.86 ppm and that of the compound bound to MEF2 was at −63.23 ppm. The CF3 resonance of the free compound without any added protein was also observed at −62.86 ppm. Chemical shifts are referenced to trifluoroacetic acid. The final DMSO concentration in the samples was below 0.05%.

Crystallization and data collection

The DNA used in crystallization was the same as previously described (23) and purified as previously reported (21). The MEF2A (1–78)/BML-210/DNA complex was prepared in two steps. First, MEF2A (1–78) at 0.5 mg/ml was mixed with 10% volume of 10 mM BML-210 in DMSO and concentrated using a Biomax 5K cut-off filter (Millipore) to a final concentration of 17 mg/ml. In the second step, the MEF2A(1–78)/BML-210/DNA complex was prepared by mixing the protein/BML-210 complex and DNA at a 2:1 molar ratio. The amount of DMSO was adjusted back to 10% volume to ensure drug solubility before setting crystal trays. Crystals were grown at 18°C by the hanging drop method with a reservoir buffer of 24% PEG 4K, 50 mM Tris HCl, pH 8.18, 3.3% glycerol, 142 mM NaCl, 5 mM MgCl2, 10 mM CaCl2 and 0.004% NaN3. Plate-like crystals grew to 50–100 μm overnight. Crystals were stabilized in a harvest/cryoprotectant buffer (30% PEG 4K, 50 mM Tris HCl, pH 8.18, 1 mM BML-210, 18% glycerol, 142 mM NaCl, 5 mM MgCl2, 10 mM CaCl2, 0.004% NaN3) and flash frozen in liquid nitrogen for storage and data collection. Data were collected at a home X-ray source (copper anode on a Rigaku
null
with an apparent IC$_{50}$ of $\sim$5 $\mu$M (Figure 1D). BML-210 did not reduce the expression of HDAC4-VP16 (Supplementary Figure S1g) but did reduce a reporter signal driven by GAL4-VP16 by 5.6 fold at 10 $\mu$M (Supplementary Figure S1h), indicating non-specific inhibition by this compound on the expression of luciferase activity under our experimental conditions. However, the same concentration of BML-210 decreased the reporter signal driven by GAL4-MEF2 and HDAC4-VP16 by about 26 fold (Supplementary Figure S1h), suggesting that BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction beyond its general inhibitory effect. Similarly, analogs of BML-210 inhibited the MEF2:HDAC4-VP16 reporter signal in transfected monkey kidney cells (COS-7) (Figure 1E) and in mouse embryonic fibroblast cells (NIH 3T3) (Figure 1F). None of the cell lines showed inhibitor-induced cell death under our experimental conditions. In contrast, Trichostatin A (TSA), a potent HDAC inhibitor that has been shown to bind the catalytic site of HDAC (29), did not show dose-dependent inhibition of the HDAC4-VP16-mediated reporter signal (Figure 1G) in HeLa cells. TSA reduced the HDAC4-VP16 luciferase response by only 1.4 fold at its IC$_{50}$ value of 100 nM while reducing the GAL4-VP16 reporter signal by $\sim$2.7 fold (Supplementary Figure S1i and S1j). These observations

Figure 1. Identification of small molecule inhibitors of the HDAC4:MEF2 interaction. (A) A structural model of the binding interface between HDAC4 (gray) and MEF2 (red and yellow). (B) Analyzing the binding interaction between HDAC4 to MEF2 using structure-guided mutations in the mammalian two-hybrid assay in HeLa cells. (C) Chemical structures of PAOA and BML-210. (D) Dosage-dependent inhibition of the reporter signal driven by HDAC4:MEF2 interaction with BML-210 in HeLa cells. (E, F) Effect of BML-210 analogs on the HDAC4:MEF2-mediated luciferase response in COS-7 cells (E) and NIH 3T3 cells (F). (G) Effect of TSA on the luciferase response driven by HDAC4:MEF2 in HeLa cells.
suggest that the catalytic inhibition of HDAC is unlikely the cause of the reduction of the luciferase response in the two-hybrid assay. Taken together, our data suggest that BML-210 and its analogs can inhibit HDAC4:MEF2 interaction inside cells.

Biochemical characterization of the BML-210:MEF2 interaction

To further analyze the binding interaction between BML-210 and MEF2, we synthesized a number of fluorine-containing analogs of BML-210 for 19F NMR analysis (Supplementary Figure S2a). One of these compounds, termed NKL54 (Figure 2A), inhibited the HDAC4:MEF2-driven luciferase signal (Figure 2B) and showed a characteristic peak in the 19F NMR spectrum. Incubation of NKL54 with MEF2A (1–95) produced a new peak at the upper field (Figure 2C), while increasing the concentration of MEF2 resulted in a larger peak at the upper field and correspondingly a smaller peak at the lower field (Figure 2D). Based on titration analyses using lower protein and ligand concentrations (Supplementary Figure S2b), the $K_d$ for the binding of NKL54 to MEF2A (1–95) was estimated to be 0.5 μM, which is close to the equilibrium-binding constant of HDAC4 to MEF2 ($K_d/C^\text{M24}/0.47\mu M$) (19). We also analyzed the effect of BML-210 on the binding of HDAC4 to MEF2 in vitro using two different methods. The first was surface plasmon resonance (SPR) on a Biacore instrument. Here, HDAC4 (AA 155–220) was immobilized on a CM5 sensor chip, and purified MEF2A (1–95) was used as the analyte. The binding of MEF2A at various concentrations to the immobilized HDAC4 generated a series of well-defined sensograms (Supplementary Figure S3a). Pre-incubation of MEF2 with increasing amounts of BML-210 decreased the binding signals (Supplementary Figure S3b). In a second approach, an HDAC4 fragment (AA 155–218) was labeled by 5-Iodoacetamidofluorescein (5-IAF) via Cys194; the binding of MEF2A (1–95) to HDAC4 (155–218) was monitored by fluorescence anisotropy (Supplementary Figure S4a). Incrementally increased amounts of BML-210 caused a gradual decay of fluorescence anisotropy, suggesting the displacement of HDAC4 from MEF2 by the small molecule (Supplementary Figure S4b). Low solubility of BML-210 in aqueous solution in both Biacore and fluorescence anisotropy assays made quantitative analysis difficult (Supplementary Data). Nevertheless, taken together, the in vitro binding data strongly suggest that BML-210 and its analogs bind MEF2 directly and competitively with HDAC4.

Structural analysis of the BML-210:MEF2:DNA complex

To analyze the structural details of the binding interaction, we co-crystallized BML-210 with MEF2A bound to DNA. The crystals diffracted to 2.4 Å. The structure was solved by molecular replacement using the MEF2A:DNA complex as the search model (23) (Supplementary Table S1). After initial rounds of rigid body refinement, electron density matching the shape of BML-210 was clearly visible in the hydrophobic pocket of MEF2 (Figure 3A). Since BML-210 has a nearly symmetric structure (Figure 1C), its orientation in the complex could not be uniquely assigned at the current resolution. However, since the ring-shaped region at one end of the electron density is surrounded by a number of hydrophobic residues including Leu66, Leu67, Thr70, Leu66', Leu67' and Thr70' (the prime sign denotes residues from the other monomer), we assigned this density to the phenyl group (Figure 3B). At the other end, the ring-like electron density is in a more hydrophilic environment surrounded by Asn73, Gln56', Asp61' and Asp63'. We assigned this density to the 2-aminophenyl group, which makes van der Waals contacts and potential hydrogen bonding interactions with residues of MEF2 (Figure 3A). It is also possible that BML-210 adopts two alternative orientations in the crystal and the observed electron density represents a weighted average of the two populations. The methylene groups of the octanediamide fit snugly between helix H2 of the two MEF2 monomers, making numerous contacts to the main chain and side chain of

![Figure 2](https://academic.oup.com/nar/article-abstract/40/12/5378/2414669/5382)
MEF2 residues, mostly of hydrophobic nature. Overall, BML-210 adopts an extended conformation to bind the surface groove of MEF2 (Figure 3D). Interestingly, a comparison with MEF2 complexes bound by Cabin1 and HDAC9 shows that BML-210 shares some binding features with natural ligands (19, 20) (Figure 3E). For example, the binding of the phenyl ring of BML-210 to the central hydrophobic pocket formed by Leu66, Leu67 and Thr70 from each monomer is analogous to that of Leu147 of HDAC9 (Figure 3E). Modeling studies also suggest that some MEF2-binding proteins, including members of the myocardin family, use an identical phenyl ring from phenylalanine to bind this pocket (21, 30).

The crystal structure can be used to guide the synthesis of BML-210 derivatives to improve the affinity and pharmacological properties. For example, the binding of BML-210 to the hydrophobic pocket of Leu66, Leu67, Thr70, Leu66', Leu67' and Thr70' is largely dependent on the phenyl group that does not completely fill the pocket, suggesting that substitutions on the phenyl ring could be an attractive strategy for optimization. The 2-aminophenyl group of BML-210, however, engages in numerous hydrogen-bond interactions with MEF2, which imposes more constraints on synthetic modifications. Another important factor is the methylene chain whose length is limited by the groove on MEF2. The narrow width of the groove also suggests that substitutions on the methylene chain may be highly limited. Considering these factors, we synthesized a series of new BML-210 analogs (Figure 4A, Supplementary Figure S2a). These compounds were designed to systematically explore the effect of ring substitutions and the length of the methylene linker on inhibiting the MEF2:HDAC4 interaction in the two-hybrid assay (Figure 4B, Supplementary Figure S2c). As shown in Figure 4B, substitutions on the phenyl rings and variations of the linker length indeed showed strong effect on inhibition of the MEF2:HDAC4 interaction. For example, compounds with a five-carbon linker were generally more active than those with a six-carbon linker. Most notably, NKL11 that lacks the putative zinc chelating 2-amino group also showed significant inhibition in the two-hybrid assay. By contrast, NAP1407, a close analog of the benzamide HDAC inhibitor MS275, is completely inactive. These observations suggest that BML-210 and its derivatives act outside the catalytic site of HDAC to inhibit the MEF2:HDAC4 interaction.

### BML-210 blocks MEF2-dependent recruitment of HDAC4 to DNA

BML-210 has been shown to enhance the expression of frataxin in Friedreich’s ataxia (FRDA), a neurodegenerative disease associated with trinucleotide repeat expansion that apparently leads to epigenetic silencing of the FXN gene (24, 31). Although the mechanism seems to involve induced histone acetylation, more potent and non-discriminatory HDAC inhibitors such as SAHA did not activate the expression of frataxin, suggesting that...
BML-210 may target a specific complex or complexes involved in frataxin expression (24).

To further explore the role of MEF2 in frataxin expression, we analyzed the promoter region of the FXN gene for putative MEF2 binding sites. We found four highly conserved A/T rich elements that resemble the consensus MEF2-binding sequence (5'-CTA(A/T)4TAG-3') approximately 200 bp upstream of the transcription start site (Supplementary Figure S5a). These putative MEF2 sites are located in the MIR (mammalian-wide interspersed repeats) region of the frataxin promoter that had been previously reported to contribute significantly to the activity of the frataxin promoter (32). Recent studies also show that SRF, another MADS-box transcription factor that shares a similar DNA binding site with MEF2, regulates the expression of Frataxin in human cells (33). We detected the enrichment of MEF2 at the FXN promoter in the FRDA cells using ChIP (Supplementary Figure S5b). Therefore, to see if BML-210 could mediate its effect on frataxin expression by disrupting MEF2/co-repressor complexes, we analyzed the binding of MEF2 and HDAC4 to the frataxin promoter using ChIP in transfected cells. We showed that MEF2 could bind and recruit HDAC4 to the frataxin promoter (Figure 5A). Treatment of the cells with BML-210 blocked this recruitment, evident by diminished binding of HDAC4 (Figure 5B), but had little effect on the occupancy of the locus by MEF2 (Figure 5C). This effect is not due to reduced expression of HDAC4 (Supplementary Figure S5c), but consistent with BML-210-mediated inhibition of HDAC4 binding to MEF2. The results presented here suggest that BML-210 could block the binding of HDAC4 to MEF2-targeted promoters in vivo.

**BML-210 analogs alter the cellular localization of HDAC4 in vivo**

Previous studies have shown that direct binding to MEF2 is required for nuclear targeting of HDAC4 and mutation of the key MEF2-binding residue Leu175 in HDAC4 resulted in a diffusive distribution of HDAC4 in the cytoplasm (18). To see if BML-210 and its analogs can mimic this effect in vivo, we analyzed the cellular localization of HDAC4 in COS-7 cells and FRDA lymphoid cells using immunocytochemistry (Figure 6A, C). Since the compounds NKL30 and NKL54 seem to be more soluble than BML-210 and more potent in inhibiting the MEF2 and HDAC4 interaction in the luciferase assay (Figure 4B), these compounds were used for the immunocytochemistry experiments. Cells were treated with 10 μM NKL30 overnight (ON) and immunostained with antibodies against MEF2 and HDAC4. Drug treatment did not result in significant cytotoxicity under the assay conditions. As shown in Figure 6A, NKL30 treatment clearly induced a much more diffusive localization pattern of HDAC4 (lower right panel) compared to the vehicle (upper right panel). Since the amount of nuclear MEF2 did not change significantly (P > 0.25) between
drug-treated and vehicle-treated samples (Supplementary Figure S6a and S6b), MEF2 was used for staining the nucleus and also for normalizing the nuclear HDAC4 level for quantitative analysis. The data indicated that the NKL30-treated cells have 21% less HDAC4 in the nucleus ($P < 0.001$) (Figure 6B). We also detected the effect of NKL54 on the cellular distribution of HDAC4 in the FRDA lymphoid cell line (GM15850) (Figure 6C). NKL54 decreased the co-localization of MEF2 and HDAC4 compared to the vehicle. There was no apparent effect on the nuclear localization of MEF2. Although we could not quantify the effect of NKL54 on the cellular localization of HDAC4 in the COS-7 cells, suggests that BML-210 and its analogs can disrupt MEF2:HDAC4 co-localization in vivo, presumably through the inhibition of MEF2:HDAC4 interaction.

**DISCUSSION**

In this study, we have demonstrated that the interaction between class IIa HDACs and MEF2 can be inhibited by small molecules. We have identified a class of compounds belonging to the PAOA family that bind MEF2 at the same site as class IIa HDACs and inhibit their binding interactions. We have also shown that these compounds can block the recruitment of class IIa HDACs to MEF2 targeted promoters without affecting the occupancy of MEF2 on DNA. Our findings suggest that the observed effect of PAOA compounds on the level of histone acetylation and gene expression (24) may include an indirect effect on the inhibition of MEF2 and class IIa HDAC interaction.

BML-210 or PAOA-like compounds were originally discovered as HDAC inhibitors that selectively induced acetylation of histone but not tubulin (28,34), presumably through the inhibition of HDACs other than HDAC6, a tubulin-specific deacetylase (35,36). The molecular mechanisms by which these benzamide derivatives inhibit HDAC function have remained unclear. The evidence of direct binding to MEF2 presented here suggests a previously unknown mechanism for the action of these molecules that does not involve targeting the active site of HDAC, but rather the protein–protein interactions between HDAC and its functional partners. In fact, these results provide the first example of subtype-selective inhibition of HDACs by targeting the protein complex between class IIa HDACs and MEF2. We have shown that these compounds, consistent with this model, can disrupt the co-localization of a class IIa HDAC and MEF2 in vivo.

Additionally, a number of our observations suggest that the FXN gene, a previously unknown target of MEF2, might be regulated by MEF2. Close examination of the FXN promoter revealed a number of conserved MEF2 binding sites in an enhancer region previously shown to be important for frataxin expression (32). ChIP analyses have shown that MEF2 binds this region in vivo. In fact, in transiently transfected cells, the class IIa HDAC member HDAC4 was shown to bind this region and the binding was enhanced in MEF2 co-transfected cells, suggesting a MEF2 mediated recruitment. Although our efforts as well as others to analyze the role of endogenous HDACs on the frataxin promoter in FRDA cells were unsuccessful (37), our data suggest that BML-210-like compounds activate FXN expression in Friedreich’s ataxia through MEF2-dependent mechanisms. It is possible that BML-210-like compounds may activate the expression of the FXN gene by blocking MEF2-mediated recruitment of transcription co-repressors other than HDACs, such as Cabin1 (20). This model provides a plausible explanation for the intriguing observations that a number of compounds, such as 7b, 10b, and 14b described by Hermann.
Figure 6. BML-210 analog NKL30 disrupts MEF2: HDAC4 co-localization in vivo. (A) Analysis of the cellular localization of MEF2 and HDAC4 in COS-7 cells treated with DMSO and NKL30 using immunocytochemistry, showing that NKL30 induced a delocalization of HDAC4 but showed no apparent effect on the cellular distribution of MEF2. The arrows point at the nucleus of a DMSO treated COS-7 cell and an NKL30 treated COS-7 cell. (B) Quantitative image analysis showing that NKL-30 reduced the amount of HDAC4 in the nucleus by 21% (P < 0.001). (C) Immunocytochemistry showing cellular localization of MEF2 (red) and HDAC4 (green) in FRDA lymphoid cell line (GM15850) treated with DMSO and NKL54. NKL54 induced delocalization of HDAC4. There was no apparent effect on the cellular distribution of MEF2 in the FRDA cells.
et al., are potent inducers of the FXN gene, while they lack the characteristic functional groups of HDAC inhibitors (24). These compounds showed little or no inhibition on HDAC activity yet enhanced the expression of the FXN gene substantially (24). Characterizing the details of the FXN induction mechanisms will require further studies. The compounds developed here can be used for dissecting the function of MEF2 and class IIa HDACs in FXN regulation and other cellular processes.

Recent studies reveal that MEF2 is highly mutated in non-Hodgkin lymphoma (15,16). Most of the mutations are amino acid substitutions at or near the cofactor recruitment sites defined by our crystal structures (15,19,20,38,39), suggesting that deregulated interactions between MEF2 and its co-activators (CBP/p300) and/or co-repressors (class IIa HDACs) may be involved in tumorigenesis. Supporting this hypothesis are observations that CBP/p300 and class IIa HDACs are also frequently mutated or deregulated in lymphoma/leukemia and other types of cancers (11,16,39). Remarkably, BML-210 has been shown to induce growth inhibition, apoptosis and differentiation in several leukemia cell lines (40). Whether BML-210 acts through MEF2 to exert its anti-tumor effect will require further studies. The structure and biochemical assays established here helped us develop more specific and potent small molecule inhibitors that can be used to address this question and analyze the function of MEF2 and class IIa HDACs. We have synthesized a series of new compounds that inhibit the interaction between MEF2 and class IIa HDACs. Some of these compounds were several folds more potent than BML-210 in inhibiting the interaction. Therefore, our results and newly introduced compounds provide leads for developing potential epigenetic therapies against multiple diseases in which deregulation of MEF2 and class IIa HDACs is implicated.

ACCESSION NUMBERS

RCSB Protein Data Bank: coordinates and structural factors have been deposited under the accession code 3MU6.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online: Supplementary Figures 1–6, Supplementary Table 1, Supplementary Methods and Supplementary References [19,21,32,41–45].

ACKNOWLEDGMENTS

The authors would like to thank Z. Chen and Dr. S. Li for help with protein preparation; Dr. M. Goodman, Dr. N. Chelyapov and USC NanoBiophysics Core Facility for assistance in Biocore and fluorescence anisotropy studies; Dr. T. Williams for assistance in the NMR studies; Dr. D. Arnold and V. Balasanyan for help with immunocytochemistry; Dr. X. Chen, R. Kalhor and Dr. G. Tao for helpful discussions; Dr. X. J. Yang and Dr. X. Liu for providing MEF2 and HDAC4 plasmids; Dr. J. Tower, Dr. N. Arnheim, Dr. N. Chen and J. Brown for help with expression and ChIP analyses; ALS BCSB members for help with data collection.

FUNDING

National Institute of Health challenge grant (RC1 DA028790 to L.C. and N. A. P.; R01 HL076334 to L.C.); two grants for NMR spectrometers by National Science Foundation (DBI-0821671); National Institute of Health (IH S10-RR25432). Funding for open access charge: National Institutes of Health.

Conflict of interest statement. None declared.

REFERENCES


